Site is Being Upgraded

Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 16/June/2017, 7.07 pm

Carbon monoxide-based therapy for body weight control, energy homeostasis and TIIDM: COR-M2( CO releasing molecule-2 )inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 14/June/2018, 11.18 pm
June 14, 2018
The miracle herb Holy basil (Tulsi) may help you live longer: Ursolic acid-based combinatorial therapy for Lifespan extension: A therapeutic mix encompassing Ursolic acid, Catalpol, Isoliquiritigenin, Maresin, DIM, Ursolic acid  Lutein, Maresin, Cholecalciferol (UCIMDULMC) activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via up regulation of its target gene ATG5 (Autophagy related 5), 16/June/2018, 11.30 pm
June 16, 2018
Show all

Introduction: What they say:

A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, 80802, Munich, Germany; and Mount Sinai, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA shows that “Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling.” This study was published, in the 20 November 2018 issue of the journal “Nature communications (One of the best journals in general science with an impact factor of 12+), by Prof Engelhardt, Sassi and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene

#


From significance of the study to Public Health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases from 2030 onwards; (6) over 240 lakhs people suffer from heart failure globally, with only treatment option being the heart transplant, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Cardiac stress, in long-term, has been shown to promote pathologic hypertrophy; and fibrosis of the myocardium. Recently, Prof. Engelhardt’s research team has shown that MiRNA-29: (1) augments pathologic hypertrophy; (2) promotes cardiac dysfunction; and (3) deletion or antisense: (a) prevents cardiac hypertrophy; (b) prevents fibrosis; (c) activates the Wnt pathway components, such as GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, suggesting that agents that decrease the expression of MiR-29 in adult cardiomyocytes may inhibit wnt pathway and improve cardiac function by attenuating cardiac hypertrophy and pathologic fibrosis.


From Research Findings to Therapeutic Opportunity:

This study provides a natural product-based therapy for cardiac hypertrophy and fibrosis. A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG), by increasing the expression of its target genes, it may decrease the expression of miR-29 (fig.1). Thereby, it may: (1) increase the expression of GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2; (2) inhibit wnt pathway; (3) increase the expression of a number of other gene products that attenuate cardiac hypertrophy and pathological fibrosis; and (4) prevent cardiac hypertrophy (fig 1). Thus, by treating patients with CMG, one may prevent pathological cardiac hypertrophy and fibrosis of the myocardium. Together, this study suggests, for the first time, that a pharmacological formulations encompassing “βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) or their analogs, either alone or in combination with other cardioprotective drugs,” may be used to improve cardiac function by attenuating cardiac hypertrophy and pathologic fibrosis (fig. 2).

Figure 1. A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) functions as a Cardioprotective agent. Mechanistic insights into how CMG decreases the expression of MiR-29 and other genes that attenuate cardiac hypertrophy and fibrosis.

Figure 2. CMG functions as a cardioprotective agent against cardiac hypertrophy and fibrosis. CMG attenuates cardiac hypertrophy and fibrosis through down regulation of MiR-29.

[easy_payment currency=”USD”]

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does CMG decrease the expression of MiR-29 and attenuate cardiac hypertrophy and fibrosis?

Amount: $750 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 16/June/2017, 7.07 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.